OVID - Ovid Therapeutics Inc Price Target Chart

Corporate company logo of Ovid Rx (OVID)

Ovid Therapeutics Inc. (OVID) possesses significant market influence through the creation of unique molecules for the therapy of rare types of epilepsy. Business development relies on partnerships with major biopharmaceutical players in the field of neuroscience. The current strategy is based on licensing payments to advance R&D, with the key metric standing at 6.39. The asset's market dynamics are illustrated in the chart below.

Ovid Rx (OVID): Analyst Consensus Forecast from 07/04/2022 to 11/12/2026
Manufactured products of Ovid Rx

For Ovid Therapeutics Inc. (OVID), which funds drug development through accumulated capital, the consensus projected stock value reflects market expectations regarding the success of clinical trials. This indicator aggregates target prices from leading analysts, establishing a fundamental benchmark for the balance of supply and demand. While a high valuation confirms the effectiveness of management's strategy, it reduces the asset's margin of safety against potential market shocks.

Competitors of Ovid Therapeutics Inc.

BIIB - Average Forecast Price|Neurocrine Biosciences, Inc. - Consensus Target|Regencell Bioscience Ltd - Price Target Chart|Axsome Therapeutics Inc - Analyst Consensus Forecast|Analyst Median Target ACADIA Corp ACAD|XENE: Analyst Consensus Forecast|Broker Consensus Forecast VKTX|Price Target Chart Supernus|Broker Consensus Forecast CPRX (Catalyst Pharma)|Analyst Consensus Forecast DNLI|HRMY - Average Forecast Price|Biohaven Ltd. - Consensus Target|Analyst Consensus Forecast amylyx.com AMLX|TRVI - Price Target Chart|Fair Value Consensus PRAX (Praxis Precision Medicines Inc)|Anavex Corp (AVXL) - Price Target Chart|Average Forecast Price CeriBell EEG (CBLL)|Price Target Chart Prothena Corporation PLC|Average Forecast Price Alector Therapeutics ALEC|Consensus Target ANNX (Annexon)|Price Target Chart OMER (omeros.com)|Analyst Consensus Forecast NGNE (Neurogene Corp)|Analyst Median Target AC Immune Inc (ACIU)|Voyager Therapeutics - Analyst Consensus Forecast|NMRA (neumoratx.com) - Broker Consensus Forecast|SCLX (Scilex) - Consensus Target|Tevogen Bio Holdings Inc. - Fair Value Consensus|Consensus Target ACOG|CGTX (cogrx.com) - Analyst Forecast Prices|Analyst Consensus Forecast IKT|SAVA (cassavasciences.com) - Fair Value Consensus|Analyst Consensus Forecast ASRT (Assertio)|Coya Therapeutics Inc (COYA) - Average Forecast Price|VTGN - Price Target Chart|Fair Value Consensus ABOS (Acumen Pharmaceuticals, Inc)|CRVO: Analyst Consensus Forecast|Alterity Therapeutics Limited (ATHE) - Analyst Consensus Forecast|Price Target Chart Clene Inc|PepGen Corp - Forecast Levels Chart|Analyst Consensus Forecast JUNS|RLMD - Average Forecast Price|Annovis Bio, Inc. - Consensus Target|Analyst Consensus Forecast Grace Therapeutics Inc GRCE|AIFF: Consensus Target|Klotho Neurosciences Inc - Analyst Forecast Prices|NRSN: Analyst Consensus Forecast|RVPH - Analyst Median Target|MTVA (MetaVia Inc.) - Analyst Consensus Forecast|Consensus Target neuraxis.com (NRXS)|Price Target Chart Helius Medical (HSDT)|Analyst Median Target passagebio.com|Neuphoria Therapeutics - Consensus Target|Fair Value Consensus NERV|Athira Pharma, Inc. - Analyst Consensus Forecast|Analyst Median Target addextherapeutics.com ADXN|alzamend.com (ALZN) - Price Target Chart|Broker Consensus Forecast CYCN|PTIX (Protagenic Therapeutics Inc.) - Analyst Consensus Forecast|Consensus Target Pasithea (KTTA)|Consensus Target CRGT (Cortigent, Inc.)|Analyst Median Target avenuetx.com|Price Target Chart BrainStorm Cell Therapeutics BCLI|Cara Therapeutics Inc. (CARA) - Average Forecast Price|CHRO: Consensus Target|ELYM: Price Target Chart|ITCI: Analyst Consensus Forecast|LBPH - Analyst Median Target|MRNS (Marinus Pharmaceuticals, Inc.) - Analyst Consensus Forecast|Broker Consensus Forecast NKGN (NKGen Biotech Inc)|Price Target Chart NeuroBo (NRBO)|Sage Therapeutics Inc - Broker Consensus Forecast|Analyst Consensus Forecast SNPX (Synaptogenix, Inc.)|trevena.com (TRVN) - Average Forecast Price|VIGL: Consensus Target|WENA - Analyst Consensus Forecast|Cerevel (CERE) - Price Target Chart